CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 94,367	$ 89,959
Short-term marketable securities	53,149	83,506
Receivables from collaborative arrangements	12,277	14,065
Amounts due from TRC, LLC	35,559	43,534
Prepaid clinical and development services	4,742	10,245
Other prepaid and current assets	4,542	8,561
Total current assets	204,636	249,870
Property and equipment, net	13,236	13,657
Operating lease assets	39,349	39,690
Equity in net assets of TRC, LLC	94,108	67,537
Restricted cash	836	837
Other assets	3,194	3,228
Total assets	355,359	374,819
Current liabilities:
Accounts payable	1,510	3,098
Accrued personnel-related expenses	9,560	12,796
Accrued clinical and development expenses	8,922	17,010
Accrued general and administrative expenses	4,412	2,898
Accrued interest payable	5,841	3,940
Current portion of non-recourse notes due 2035, net	9,012	16,940
Operating lease liabilities	4,054	503
Deferred revenue	98	98
Other accrued liabilities	792	1,304
Total current liabilities	44,201	58,587
Convertible senior notes due 2023, net	228,303	228,035
Non-recourse notes due 2035, net	384,161	371,359
Long-term operating lease liabilities	47,415	52,681
Long-term deferred revenue	301	310
Other long-term liabilities	2,428	2,420
Commitments and contingencies
Shareholders' Deficit
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 76,081 and 74,435 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	1	1
Additional paid-in capital	1,400,566	1,387,469
Accumulated other comprehensive loss	(28)
Accumulated deficit	(1,751,989)	(1,726,043)
Total shareholders' deficit	(351,450)	(338,573)
Total liabilities and shareholders' deficit	$ 355,359	$ 374,819